Hexaell Biotech
Latest round
- Series B
Last raised
- Apr 2026
Total raised
- $49M
Investors
- 10
About Hexaell Biotech
, dba Hexaell Biotech, operates as a biotechnology company specializing in developing novel cell therapies and regenerative medicines for severe liver diseases. In July 2017, the company established a production line for clinical research and development of human hepatocyte-derived bioartificial liver in Jiading, Shanghai. Hexaell Biotech focuses on severe liver diseases and cell therapy. It uses hepatocyte trans-differentiation and expansion technology to build the HepaCure bioartificial liver support system, which is an in vitro liver function support system suitable for patients with liver failure and postoperative rehabilitation of patients with liver resection. The company also uses primary hepatocyte in vitro expansion technology to build proliferating human primary hepatocytes ProliHH, which can be used for hepatocyte transplantation to treat genetic metabolic liver diseases, and drug screening and other R&D services. The company generates revenue by providing bioartificial liver products and hepatocyte transplant products, as well as developing cell therapy technologies.
Who invested in Hexaell Biotech
10 investors across 4 rounds
See all investors in Hexaell Biotech
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hexaell Biotech
Who invested in Hexaell Biotech?
Hexaell Biotech has 10 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hexaell Biotech raised?
Hexaell Biotech has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Hexaell Biotech last raise money?
Hexaell Biotech's most recent round on record is a Series B, in Apr 2026.
What does Hexaell Biotech do?
, dba Hexaell Biotech, operates as a biotechnology company specializing in developing novel cell therapies and regenerative medicines for severe liver diseases.
Where is Hexaell Biotech headquartered?
Hexaell Biotech is headquartered in Shanghai, China.
Which VCs invest in companies like Hexaell Biotech?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Hexaell Biotech's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Hexaell Biotech? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.